Skip to main content

ACCENDRA HEALTH INC

corporate_fare Company Profile

ACCENDRA HEALTH INC

OMI·NYSE·Healthcare·CIK 0001125001

ACCENDRA HEALTH INC is a biopharmaceutical company focused on the discovery, development and commercialization of vaccines and immune system stimulants delivered to the skin via a novel, needle-free technology called transcutaneous immunization, or TCI. TCI exploits the unique benefits of Langerhans cells, a major group of antigen-presenting cells found in the outer layers of the skin, to generate an enhanced immune response. TCI has the potential to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. None of its product candidates has been approved for commercial sale by the U.S. Food and Drug Administration or any comparable foreign agencies. The company is developing two distinct product applications: (1) a needle-free vaccine patch and (2) an immunostimulant, or IS, patch. It currently has four product candidates in development: one to prevent travelers' diarrhea and three targeting influenza. The four product candidates are (1) a needle-free travelers' diarrhea vaccine patch, (2) an IS patch intended to stimulate an immune response to even small doses of a pandemic flu vaccine, thereby extending vaccine supply in the event of an influenza pandemic, (3) a needle-free vaccine patch for seasonal flu, and (4) an IS patch intended to boost the immune response of the elderly to the standard flu vaccine. For the needle-free travelers' diarrhea vaccine patch, in September 2007 the company presented data from a Phase 2 field trial at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicating that people who received the vaccine before traveling to Mexico or Guatemala were significantly less likely to report clinically significant diarrhea. Of the 59 individuals who received the vaccine, only three suffered moderate or severe diarrhea, while 23 of the 111 who received a placebo suffered moderate or severe diarrhea, a 75 percent reduction (p=0.007). One of the 59 volunteers in the vaccine group reported severe diarrhea, compared with 12 of the 111 in the placebo group, an 84 percent reduction (p=0.033).

ACCENDRA HEALTH INC (NYSE:OMI) is a publicly traded company in the Healthcare sector. Wiseek has independently scored 1 item for OMI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-01-05, rated 9/10. Recent SEC coverage for OMI spans 8-K/A.

Recent high-impact activity:

  • Accendra Health Files Pro Forma Financials for $375M P&HS Business Sale and $280M Debt Repayment
$2.86
Market cap
$216.57M
Volume
1.3M (0.7× avg)
3-mo avg 1.9M
Last traded · 2026-01-02

show_chartPrice Chart

Loading chart...

feed OMI - Latest Insights

OMI
Jan 05, 2026, 4:06 PM EST
Filing Type: 8-K/A
Importance Score:
9
Price at Filing: $2.86
Real-time Price: $2.86 info
Change: $0 (0%) info
Market Cap: $216.57M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets